Dipeptidyl peptidase-4

DGAP-News: Interdepartmental testing of the kidney function biomarker penKid in routine care at Heidelberg University Hospital and the Heidelberg Kidney Center

Retrieved on: 
Friday, August 26, 2022
Nexus, Mortality, Inflammation, CA, Renal replacement therapy, Hospital, Hennigsdorf, Disease, Clinic, Shock, Kinetics, PMID, AKI, Critical care, IMC, NZH, University Hospital Heidelberg, Standard of care, Sepsis, Immunoassay, Diagnosis, Prognosis, IVD, Dialysis, Dipeptidyl peptidase-4, CSO, Nephrology, Wang, High-dependency unit, Anesthesiology, Patient, Heart, CRRT, Kidney, Acute kidney injury, Biomarker, Jean-Louis Vincent, ICU, DPP3, Medical imaging, Medical device

Four units at the University Hospital Heidelberg and Heidelberg Kidney Center implement Proenkephalin (penKid) in a pilot biomarker-based treatment approach to diagnose AKI faster and monitor it more accurately across departments.

Key Points: 
  • Four units at the University Hospital Heidelberg and Heidelberg Kidney Center implement Proenkephalin (penKid) in a pilot biomarker-based treatment approach to diagnose AKI faster and monitor it more accurately across departments.
  • PenKid is a proposed biomarker for real-time kidney function that potentially closes on the gaps of the standard diagnostic procedures.
  • This includes the normal, the intermediate care (IMC), the nephrology, and the intensive care units (ICU) of both clinics in Heidelberg.
  • This routine use of penKid on a centralized level in the hospital drives innovation on multiple wards such as nephrology, ICU and IMC.

Global DPP-IV Inhibitors Industry

Retrieved on: 
Tuesday, April 14, 2020
Dipeptidyl peptidase-4, Peptidase, Dipeptidyl peptidase-4 inhibitors

NEW YORK, April 14, 2020 /PRNewswire/ --DPP-IV Inhibitors market worldwide is projected to grow by US$1.7 Billion, driven by a compounded growth of 2.6%.

Key Points: 
  • NEW YORK, April 14, 2020 /PRNewswire/ --DPP-IV Inhibitors market worldwide is projected to grow by US$1.7 Billion, driven by a compounded growth of 2.6%.
  • DPP-IV Inhibitors, one of the segments analyzed and sized in this study, displays the potential to grow at over 2.6%.
  • Poised to reach over US$10.4 Billion by the year 2025, DPP-IV Inhibitors will bring in healthy gains adding significant momentum to global growth.
  • In Japan, DPP-IV Inhibitors will reach a market size of US$747.8 Million by the close of the analysis period.

Dipeptide Peptidase 4 (DPP-4) Inhibitors: Global Market 2019-2024 - The Tradjenta Market will Surpass Merck's Januvia During the Forecast Period - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 3, 2019
Health, Pharmaceutical, Chemical compounds, Dipeptidyl peptidase-4 inhibitors, Organic compounds, Chemistry, Dipeptidyl peptidase-4, Sitagliptin, Linagliptin, Forecast period, Compound annual growth rate, Vildagliptin

The "Dipeptide Peptidase 4 (DPP-4) Inhibitors Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dipeptide Peptidase 4 (DPP-4) Inhibitors Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.
  • Increase in clinical trials on the DPP-4 drugs will also boost the market growth in the forecast period.
  • The global Tradjenta market is expected to register a CAGR of 5.7 %, during the forecast period, 2019-2024, and is expected to surpass the Januvia market, which held the maximum market share in 2018.
  • The Asia-Pacific holds 32% of the market share in the global DPP-4 market, followed by North America, which holds the highest market share.

TriNetX Real-World Evidence Platform Validates Outcomes of Randomized Clinical Trials

Retrieved on: 
Tuesday, December 18, 2018
Health, Clinical research, Peptidase, Design of experiments, Medical research, Evidence-based practices, Anti-diabetic drugs, Dipeptidyl peptidase-4, Dipeptidyl peptidase, Randomized controlled trial, SGLT2, Clinical trial

CAMBRIDGE, Mass., Dec. 18, 2018 /PRNewswire/ --TriNetX, the global health research network that revolutionizes clinical research and enables discoveries through the creation of real-world evidence (RWE), today announced the results of a study confirming that the TriNetX platform successfully leverages real-world data (RWD) to generate RWE to replicate results from randomized clinical trials (RCTs).

Key Points: 
  • CAMBRIDGE, Mass., Dec. 18, 2018 /PRNewswire/ --TriNetX, the global health research network that revolutionizes clinical research and enables discoveries through the creation of real-world evidence (RWE), today announced the results of a study confirming that the TriNetX platform successfully leverages real-world data (RWD) to generate RWE to replicate results from randomized clinical trials (RCTs).
  • The study compared the records of 46,909 patients who had taken SGLT2 inhibitors with 189,120 patients who had taken dipeptidyl peptidase-4 (DPP4) inhibitors.
  • "This cardiovascular study is just one of many examples of how the TriNetX platform is helping the research community generate real-world evidence faster and more easily than ever possible before."
  • TriNetX combines real time access to longitudinal clinical data with state-of-the-art analytics to answer complex research questions at the speed of thought.